אימנד 80 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
אימנד 80 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
אימנד 80 מג קפסולות
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
אימנד 125 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
אימנד 125 מג קפסולות
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
אימנד 125 מג קפסולות
merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant
אימנד 150 מ"ג iv
merck sharp & dohme israel ltd - fosaprepitant as fosaprepitant dimeglumine 150 mg - powder for solution for infusion - aprepitant - emend iv 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
פאלוקסי זריקות
rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
פאלוקסי זריקות
rafa laboratories ltd - palonosetron as hydrochloride - תמיסה להזרקה - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
אקינזאו
rafa laboratories ltd - netupitant; palonosetron as hydrochloride - קפסולות - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations